1 June 2023 – EyRIS, a pioneering company in artificial intelligence (AI) healthcare solutions, and Optometrist Warehouse, part of the Chemist Warehouse Group in Australia, have signed a Memorandum of Understanding (MOU) to collaborate on a ground-breaking study focused on the effectiveness of AI in screening diabetic retinopathy. This collaboration marks a significant milestone in the field of healthcare, showcasing the potential benefits of AI-driven solutions in improving patient outcomes and cost-effectiveness.
Diabetic retinopathy, a common complication of diabetes, is a leading cause of blindness among adults globally. According to the Australian Diabetes Society, over 1.5 million Australians are currently living with diabetes, and this number is projected to increase significantly over the next decade. Early detection and intervention are crucial to prevent vision loss and related complications.
The study will leverage EyRIS’s advanced AI algorithms and Optometrist Warehouse expertise with links to the extensive network of pharmacies across Australia of Chemist Warehouse to evaluate the effectiveness of AI-driven screening for diabetic retinopathy. By using EyRIS’s cutting-edge technology, which analyses retinal images for signs of diabetic retinopathy, the study aims to demonstrate the efficacy and efficiency of AI in identifying patients at risk and facilitating early intervention.
Mr. Lai Teik Kin, CEO of EyRIS, expressed his enthusiasm about the collaboration, stating, “We are thrilled to partner with Optometrist Warehouse on this ground-breaking study. By harnessing the power of AI, we can revolutionize diabetic retinopathy screening, ensuring early detection and timely treatment for patients. Our technology has the potential to transform healthcare delivery, saving lives and reducing healthcare costs.”
Optometrist Warehouse, with an innovative mission to transforming health outcomes by systematically connecting pharmacy with optometry, recognizes the transformative impact of AI in the field of medicine. Mr. Peter Larsen, MD of Optometrist Warehouse, and a recognised leader in eye health service improvement, stated, “We are proud to collaborate with EyRIS to explore the possibilities of AI in diabetic retinopathy screening. This study aligns with our mission to improve healthcare outcomes for all Australians. By leveraging EyRIS’s AI expertise, we can enhance the accessibility and affordability of early screening, thereby empowering patients and healthcare providers alike.”
The collaboration between EyRIS and Optometrist Warehouse underscores the commitment of both organizations to leverage technological advancements for the betterment of healthcare. The potential benefits of AI-driven diabetic retinopathy screening include reducing the burden on healthcare systems, minimizing unnecessary referrals, and enabling targeted interventions, ultimately improving patient outcomes.
The study will span a period of 36 months and involve a large sample size of diabetic patients across various regions in Australia.
Press release covered in the media:
EyRIS is a Singapore-based healthcare technology company specializing in AI-driven solutions for eye diseases. By combining state-of-the-art machine learning algorithms and extensive clinical expertise, EyRIS develops innovative tools for the early detection and management of eye conditions, ultimately improving patient outcomes. For more information, please visit www.eyris.io.
About Optometrist Warehouse and the Chemist Warehouse Group
Optometrist Warehouse is a disruptive start-up of the Chemist Warehouse Group seeking to transform health outcomes by connecting optometry with pharmacy and other stakeholders.
Chemist Warehouse Group is Australia’s largest retail pharmacy chain, committed to providing accessible and affordable healthcare solutions to the community. With over 500 locations nationwide, Chemist Warehouse Group offers a wide range of pharmaceutical products and professional services, ensuring the well-being of millions of Australians. For more information, please visit www.chemistwarehouse.com.au and www.chemistwarehouse.com.au/optometry.
Please direct all queries related to this article to Marketing at email@example.com
Comments are closed.